Immunotherapy for Inhalant Allergy

Publication Date: February 26, 2024

Introduction

Introduction

  • Allergic rhinitis (AR) and allergic asthma (AA) are caused by an immunoglobulin E (IgE) mediated inflammatory response to proteins (or glycoproteins) carried by inhaled organic particles such as pollen, animal dander, mold spores, and/or mite/insect debris.
  • Inhalant allergies can be treated by immunotherapy, pharmaceuticals, or by reducing environmental exposure to the allergen.
  • Inhalant allergen immunotherapy (AIT) is administered to millions of patients for AR and AA and is most commonly delivered as subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT).
  • Variability in the initiation and delivery of safe and effective immunotherapy provides opportunities for evidence-based recommendations to improve patient care.

Treatment

...reatmen...

...breviations and Definitions of Common Ter...


...2. Summary of Guideline Key Action Stat...

...sessment...

...andidacy for Allergen ImmunotherapyClin...

...uld not get Allergen ImmunotherapyClinicians...

...o may not get Allergen Immunothera...

...sthma AssessmentClinicians should evaluate the...

...ducation

...Education regarding SLIT versus SCIT...

...garding Preventive Qualities of Allergen...

Treatme...

...easonal TherapyClinicians who administer SLIT...

...ecting Clinically Relevant Allergen...

8. Treating Polysensitized Patients w...

...actions and Allergen Immunotherapy EscalationCl...

...axis Identification and ManagementThe clini...

...Retesting During Allergen ImmunotherapyClinicia...

...Duration for Allergen ImmunotherapyFor patien...


...omparison of SCIT and SLIT Modalities of AIT for...


...le 4. World Allergy Organization Subcutaneous Imm...


...-/Co-Seasonal SLIT Time CourseTime c...


...hylaxis Diagnostic Criteria Reproduced fr...


...rentiating Between Vasovagal and AnaphylaxisHavi...


...3. Management of AnaphylaxisReproduced from the W...


...igure 4. Flowchart Showing Key Action...